Target family: Dopamine receptors (type: gpcr)
Target: D<sub>3</sub> receptor

Ligand: pergolide (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1988)
Primary target: no
Median affinity: 8.300000190734863 pKi
Reference (Journal): Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
Published in: J Pharmacol Exp Ther

Ligand: PD 128907 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): A functional test identifies dopamine agonists selective for D<sub>3</sub>versus D<sub>2</sub>receptors.
Published in: Neuroreport

Ligand: PD 128907 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
Published in: J Pharmacol Exp Ther

Ligand: (-)-N-porphynorapomorphine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Expression and pharmacological characterization of the human D3 dopamine receptor.
Published in: J Pharmacol Exp Ther

Ligand: (-)-N-porphynorapomorphine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): A functional test identifies dopamine agonists selective for D<sub>3</sub>versus D<sub>2</sub>receptors.
Published in: Neuroreport

Ligand: NGB 2904 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.8 pKi
Reference (Journal): Pharmacological actions of NGB 2904, a selective dopamine D3 receptor antagonist, in animal models of drug addiction.
Published in: CNS Drug Rev

Ligand: nemonapride (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines.
Published in: J Pharmacol Exp Ther

Ligand: nemonapride (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Characterization of the human dopamine D3 receptor expressed in transfected cell lines.
Published in: Eur J Pharmacol

Ligand: nafadotride (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 9.520000457763672 pKi
Reference (Journal): Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
Published in: J Pharmacol Exp Ther

Ligand: mesoridazine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1970)
Primary target: no
Median affinity: 7.639999866485596 pKi
Reference (Journal): Synthesis, receptor binding and functional studies of mesoridazine stereoisomers.
Published in: Bioorg Med Chem Lett

Ligand: loxapine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1975), EMA (2013)
Primary target: yes
Median affinity: 7.679999828338623 pKi
Reference (Journal): Antipsychotic drugs, dopamine receptors, and schizophrenia.
Published in: Clinical Neuroscience Research

Ligand: lisuride (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: EMA (2011)
Median affinity: 9.6 pKi
Reference (Journal): Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
Published in: J Pharmacol Exp Ther

Ligand: trans-flupenthixol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 6.519999980926514 pKi
Reference (Journal): Expression and pharmacological characterization of the human D3 dopamine receptor.
Published in: J Pharmacol Exp Ther

Ligand: HS665 (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.550000190734863 pKi
Reference (Journal): Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist.
Published in: J Med Chem

Ligand: haloperidol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1967)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes.
Published in: Pharmacol Biochem Behav

Ligand: haloperidol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1967)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Asenapine: a novel psychopharmacologic agent with a unique human receptor signature.
Published in: J Psychopharmacol (Oxford)

Ligand: haloperidol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1967)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Expression and pharmacological characterization of the human D3 dopamine receptor.
Published in: J Pharmacol Exp Ther

Ligand: haloperidol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1967)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
Published in: Eur J Pharmacol

Ligand: haloperidol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1967)
Median affinity: 7 pKi
Reference (Journal): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
Published in: Nature

Ligand: flupentixol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity: 8.960000038146973 pKi
Reference (Journal): Expression and pharmacological characterization of the human D3 dopamine receptor.
Published in: J Pharmacol Exp Ther

Ligand: eticlopride (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.8 pKi
Reference (Journal): Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines.
Published in: J Pharmacol Exp Ther

Ligand: eticlopride (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.8 pKi
Reference (Journal): Characterization of the human dopamine D3 receptor expressed in transfected cell lines.
Published in: Eur J Pharmacol

Ligand: dopamine (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1974)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Lack of discrimination by agonists for D2 and D3 dopamine receptors.
Published in: Neuropsychopharmacology

Ligand: dopamine (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1974)
Primary target: yes
Median affinity:  pKi
Reference (Journal): A functional test identifies dopamine agonists selective for D<sub>3</sub>versus D<sub>2</sub>receptors.
Published in: Neuroreport

Ligand: dopamine (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1974)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
Published in: Nature

Ligand: dopamine (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1974)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Expression and pharmacological characterization of the human D3 dopamine receptor.
Published in: J Pharmacol Exp Ther

Ligand: domperidone (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): Expression and pharmacological characterization of the human D3 dopamine receptor.
Published in: J Pharmacol Exp Ther

Ligand: domperidone (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Median affinity: 7 pKi
Reference (Journal): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
Published in: Nature

Ligand: domperidone (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: yes
Median affinity:  pKi
Reference (Journal): Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
Published in: Eur J Pharmacol

Ligand: compound 3 [PMID: 23134120] (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: no
Median affinity: 6.769999980926514 pKi
Reference (Journal): Discovery and pharmacological evaluation of a diphenethylamine derivative (HS665), a highly potent and selective κ opioid receptor agonist.
Published in: J Med Chem

Ligand: clozapine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1989)
Median affinity:  pKi
Reference (Journal): Expression and pharmacological characterization of the human D3 dopamine receptor.
Published in: J Pharmacol Exp Ther

Ligand: clozapine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1989)
Median affinity: 5.7 pKi
Reference (Journal): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
Published in: Nature

Ligand: clozapine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1989)
Median affinity:  pKi
Reference (Journal): Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
Published in: Eur J Pharmacol

Ligand: chlorprothixene (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Primary target: no
Median affinity: 8.34000015258789 pKi
Reference (Journal): Potential utility of histamine H3 receptor antagonist pharmacophore in antipsychotics.
Published in: Bioorg Med Chem Lett

Ligand: chlorpromazine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1957)
Median affinity:  pKi
Reference (Journal): Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
Published in: Eur J Pharmacol

Ligand: chlorpromazine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1957)
Median affinity: 7.2 pKi
Reference (Journal): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
Published in: Nature

Ligand: chlorpromazine (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Approval source: FDA (1957)
Median affinity:  pKi
Reference (Journal): Expression and pharmacological characterization of the human D3 dopamine receptor.
Published in: J Pharmacol Exp Ther

Ligand: cariprazine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (2015), EMA (2017)
Primary target: no
Median affinity: 10.050000190734863 pKi
Reference (Journal): Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Published in: J Pharmacol Exp Ther

Ligand: cabergoline (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1996)
Median affinity: 9.1 pKi
Reference (Journal): Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
Published in: J Pharmacol Exp Ther

Ligand: (+)-butaclamol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Lack of discrimination by agonists for D2 and D3 dopamine receptors.
Published in: Neuropsychopharmacology

Ligand: (+)-butaclamol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.
Published in: J Pharmacol Exp Ther

Ligand: (+)-butaclamol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines.
Published in: J Pharmacol Exp Ther

Ligand: (+)-butaclamol (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Expression and pharmacological characterization of the human D3 dopamine receptor.
Published in: J Pharmacol Exp Ther

Ligand: bromocriptine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: yes
Median affinity:  pKi
Reference (Journal): A functional test identifies dopamine agonists selective for D<sub>3</sub>versus D<sub>2</sub>receptors.
Published in: Neuroreport

Ligand: bromocriptine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
Published in: J Pharmacol Exp Ther

Ligand: bromocriptine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: FDA (1978)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Expression and pharmacological characterization of the human D3 dopamine receptor.
Published in: J Pharmacol Exp Ther

Ligand: bromocriptine (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1978)
Median affinity: 7.1 pKi
Reference (Journal): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
Published in: Nature

Ligand: BP 897 (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: no
Primary target: no
Median affinity: 9 pKi
Reference (Journal): Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist.
Published in: Nature

Ligand: apomorphine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: EMA (2001), FDA (2004)
Primary target: yes
Median affinity:  pKi
Reference (Journal): A functional test identifies dopamine agonists selective for D<sub>3</sub>versus D<sub>2</sub>receptors.
Published in: Neuroreport

Ligand: apomorphine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: EMA (2001), FDA (2004)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Lack of discrimination by agonists for D2 and D3 dopamine receptors.
Published in: Neuropsychopharmacology

Ligand: apomorphine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: EMA (2001), FDA (2004)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Expression and pharmacological characterization of the human D3 dopamine receptor.
Published in: J Pharmacol Exp Ther

Ligand: apomorphine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: EMA (2001), FDA (2004)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
Published in: J Pharmacol Exp Ther

Ligand: apomorphine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: EMA (2001), FDA (2004)
Median affinity: 7.7 pKi
Reference (Journal): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
Published in: Nature

Ligand: apomorphine (Synthetic organic)
Interaction type: Agonist
Action: Partial agonist
Ligand approved: yes
Approval source: EMA (2001), FDA (2004)
Primary target: yes
Median affinity:  pKi
Reference (Journal): Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
Published in: Eur J Pharmacol

Ligand: amisulpride (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: yes
Median affinity: 7.4 pKi
Reference (Journal): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
Published in: Nature

Ligand: (+)-AJ76 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor.
Published in: Eur J Pharmacol

Ligand: (+)-AJ76 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6 pKi
Reference (Journal): Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics.
Published in: Nature

Ligand: (+)-AJ76 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pKi
Reference (Journal): Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
Published in: J Pharmacol Exp Ther

Ligand: 7-trans-OH-PIPAT (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.7 pKi
Reference (Journal): Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors.
Published in: J Med Chem

Ligand: 7-OH-DPAT (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): A functional test identifies dopamine agonists selective for D<sub>3</sub>versus D<sub>2</sub>receptors.
Published in: Neuroreport

Ligand: 7-OH-DPAT (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Lack of discrimination by agonists for D2 and D3 dopamine receptors.
Published in: Neuropsychopharmacology

Ligand: 7-OH-DPAT (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Characterization of the human dopamine D3 receptor expressed in transfected cell lines.
Published in: Eur J Pharmacol

Ligand: 7-OH-DPAT (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors.
Published in: J Med Chem

Ligand: 7-OH-DPAT (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pKi
Reference (Journal): Expression and pharmacological characterization of the human D3 dopamine receptor.
Published in: J Pharmacol Exp Ther